Asst Prof Tan Chia-Ken Aaron

Dr Aaron is a Medical Oncologist at the National Cancer Centre Singapore (NCCS), having completed his specialty training in Medical Oncology (FRACP) in Sydney, Australia. He also completed a PhD in cancer drug discovery at The University of Sydney in 2011. At NCCS, he completed a fellowship in drug development/early phase trials and lung cancer translational research.

• FRACP (Medical Oncology, Royal Australasian College of Physicians) 
• PhD (University of Sydney) 
• MBBS (University of New South Wales) 
• BSc(Med)Hons (University of New South Wales)

• NMRC Transition Award (2025) 
• ESMO TAT Asia Merit Award (2025)
• ESMO TAT Merit Award (2024)
• ASCO Breakthrough Merit Award (2023)
• Top 2% Most Cited Scientists Globally (2023, 2024, 2025)
• NMRC CS-IRG New Investigator Grant (NIG; 2022 & 2023) 
• A*STAR Biomedical Engineering Programme Grant (2022)
• SingHealth Publish! Award 2021 & 2022
• NCCS Cancer Fund (Research) Pilot Grant (2021)
• Early Career Education Award, WCLC 2020 (2021)
• IASLC Academy Award (2019)
• IASLC Fellowship (2018-2020)
• ESMO Asia Merit Award (2019)
• ASCO Merit Award (2018)
  

• NVL-655-01A: Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1)
• CGCJ904A12101: Phase I FIH dose escalation/expansion study to evaluate GCJ904 ([177Lu]Lu-DFC413), a radioligand therapy targeting FAP, as a single agent in multiple indications
• HMBD-001-103: A Phase 1b Study to Evaluate HMBD-001 in Combination with Docetaxel with or without Cetuximab in Participants with Advanced Squamous Non-Small Cell Lung Cancers
• V940-009: A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009)
• Bayer 22615: A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2-activating mutations

• Tan AC et al. Consensus Statement on ctDNA Minimal Residual Disease Testing in Early Stage NSCLC: A Delphi Study by the Asian Thoracic Oncology Research Group. J Thorac Oncol, 2026
• Tan AC et al. Detection of circulating tumor DNA with ultradeep sequencing of plasma cell-free DNA for monitoring minimal residual disease and early detection of recurrence in early-stage lung cancer. Cancer, 2024;130:1758-65.
• Tan AC et al. Clinical and Genomic Features of HER2 Exon 20 Insertion Mutations and Characterization of HER2 Expression by Immunohistochemistry in East Asian Non-Small-Cell Lung Cancer. JCO Prec Onc, 2022;6:e2200278.
• Tan AC, Tan DSW. Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations. J Clin Oncol, 2022;40:611-25.
• Tan AC et al. Utility of incorporating next generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: incremental yield of actionable alterations and cost effectiveness analysis. Lung Cancer, 2020;139:207-15.